The sources and characteristics of the fucoidan used in this study have been previously reported [13 (link)]. Fucoidan was diluted in Roswell Park Memorial Institute 1640 (RPMI 1640) complete medium at a concentration of 800 μg/ml. RPMI 1640 medium and fetal bovine serum (FBS) were purchased from Gibco (Life Technologies, South America). Trypsin was obtained from Hyclone (Thermo Fisher Scientific, Carlsbad, CA, USA).
The following primary antibodies were used in this study: VEGFR3, lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) and phospho-Akt (p-Akt; Santa Cruz, CA, USA); glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and cyclin-dependent kinase 4 (CDK4; Sangon Biotech, Shanghai, China); PROX1 and cyclin D1 (Boster, Wuhan, China); NF-κB (Zhongshan Biotech, Beijing, China) and p-PI3K (ImmunoWay, Newark, DE, USA).
The following primary antibodies were used in this study: VEGFR3, lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) and phospho-Akt (p-Akt; Santa Cruz, CA, USA); glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and cyclin-dependent kinase 4 (CDK4; Sangon Biotech, Shanghai, China); PROX1 and cyclin D1 (Boster, Wuhan, China); NF-κB (Zhongshan Biotech, Beijing, China) and p-PI3K (ImmunoWay, Newark, DE, USA).
Free full text: Click here
